NCT00119379View on ClinicalTrials.gov

Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
HIV InfectionsLipodystrophyMetabolic DiseasesNutrition Disorders
Interventions
DRUG

NucleomaxX

NucleomaxX 36 grams TID every other day

DRUG

Tenofovir Disoproxil Fumarate

Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate

Trial Locations (1)

44106

University Hospitals of Cleveland, Cleveland

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00119379 - Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults | Biotech Hunter | Biotech Hunter